ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO926

Analysis of PD-L1 on Kidney Vascular Endothelial Cells

Session Information

Category: Pathology and Lab Medicine

  • 1800 Pathology and Lab Medicine

Authors

  • Imai, Yoichi, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Kaneko, Yoriaki, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Kinoshita, Masato, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Suwa, Junya, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Hamatani, Hiroko, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Ikeuchi, Hidekazu, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
  • Hiromura, Keiju, Gunma University Graduate School of Medicine Department of Nephrology and Rheumatology, Maebashi, Gunma, Japan
Background

Programmed death ligand 1 (PD-L1), expressed on various types of cells including vascular endothelia, inhibits T cell activity via PD-1. Anti- PD-L1/ PD-1 antibodies block this interaction and enhance T cell cytotoxicity, which has been utilized as cancer immunotherapy. However, Anti-PD-L1/PD-1 antibodies sometimes induce interstitial nephritis with unclear etiology. This study examines PD-L1 expression on kidney endothelial cells (ECs) and its effects on T cells in mice.

Methods

Female C57BL/6j mice were used. Kidney and lung cells were isolated by collagenase treatment and density gradient centrifugation, then analyzed by flow cytometry (FCM). Glomerular cells were separated using a mesh and collagenase treatment. Specific cell populations were separated using CD45 and CD31 microbeads. Mice received intraperitoneal injections of LPS, anti- PD-L1, or anti-CD3ε antibodies.

Results

FCM analysis in healthy mice showed PD-L1 expression in ECs (CD31+CD45.2-) of both kidneys and lungs, with higher expression in kidneys. These cells also expressed other EC markers like ICAM-1 and VEGFR2. Immunofluorescence staining (IF) revealed PD-L1 co-staining in CD31+ glomerular ECs, peritubular capillary ECs, and interlobular artery ECs. Glomerular ECs had lower PD-L1 expression compared to peritubular capillary and arterial ECs. Co-culturing renal ECs with splenic cytotoxic T cells (CD8α+) induced IFN-γ secretion, significantly increased by anti-PD-L1 antibody. LPS administration increased PD-L1 expression in ECs of both kidneys and lungs. IF showed enhanced PD-L1 in glomerular and peritubular capillary ECs in kidneys with LPS injection. Anti-CD3ε antibody, inducing high IFN-γ levels, also increased PD-L1 expression in renal ECs, as shown by FCM. Blocking PD-L1 on ECs with anti-PD-L1 antibody before anti-CD3ε treatment led to increased leukocyte infiltration into the renal interstitium and elevated blood urea nitrogen levels.

Conclusion

In healthy mice, PD-L1 is primarily expressed in peritubular capillaries of the kidney, and its expression increases during inflammation. PD-L1 on kidney ECs may inhibit T cell immune activation, suggesting a protective role for the kidneys.